This T cell-based test is the first indication resulting from Adaptive s TCR-Antigen Map collaboration with
Microsoft Corporation (NASDAQ: MSFT).
Unlike other tests that detect blood-based antibodies to determine the prior infection with the virus, the T-Detect COVID-19 Test leverages immune repertoire sequencing technology to identify individuals with an adaptive T-cell response to SARS-CoV-2, indicating recent or prior infection.
The EUA was issued based on a clinical validation study demonstrating a sensitivity of 97.1% from the date of COVID-19 diagnosis with RT-PCR. The test also showed a specificity of 100%.
The FDA noted that the test should not be used to diagnose current SARS-CoV-2 infection.
Adaptive Biotechnologies Gets FDA EUA for T-Detect to Confirm Recent or Prior Covid-19 Infection
morningstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from morningstar.com Daily Mail and Mail on Sunday newspapers.
iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), (ABCL) - The Daily Biotech Pulse: Bausch Calls Truce With Icahn, Pfizer s Brain Inflammation Vaccine Gets Priority Review, BriaCell IPO
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.